Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Iovance Biotherapeutics total assets
Total assets on the balance sheet at the end of each period.
Iovance Biotherapeutics's total assets was $915.53M at Jun 30, 2026. For fiscal 2025 it was $913.17M, up 0.3% from the year before. Over ten years it grew 24.1% a year on average. The highest annual figure on record is $913.17M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $913.17M | +0.3% |
| FY2024 | Dec 31, 2024 | $910.43M | +16.7% |
| FY2023 | Dec 31, 2023 | $780.35M | +17.5% |
| FY2022 | Dec 31, 2022 | $663.98M | -14.6% |
| FY2021 | Dec 31, 2021 | $777.33M | +1.2% |
| FY2020 | Dec 31, 2020 | $768.46M | +123.0% |
| FY2019 | Dec 31, 2019 | $344.66M | -28.3% |
| FY2018 | Dec 31, 2018 | $480.82M | +209.5% |
| FY2017 | Dec 31, 2017 | $155.37M | -9.6% |
| FY2016 | Dec 31, 2016 | $171.89M | +62.7% |
| FY2015 | Dec 31, 2015 | $105.65M | +127.2% |
| FY2014 | Dec 31, 2014 | $46.51M | +134.0% |
| FY2013 | Dec 31, 2013 | $19.87M | +67467.6% |
| FY2012 | Dec 31, 2012 | $29.41K | -94.8% |
| FY2011 | Dec 31, 2011 | $568.43K | -61.1% |
| FY2010 | Dec 31, 2010 | $1.46M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $915.53M | +0.9% |
| Q1 FY2026 | Mar 31, 2026 | $925.67M | -4.2% |
| Q4 FY2025 | Dec 31, 2025 | $913.17M | +0.3% |
| Q3 FY2025 | Sep 30, 2025 | $904.95M | -8.7% |
| Q2 FY2025 | Jun 30, 2025 | $907.44M | -5.9% |
| Q1 FY2025 | Mar 31, 2025 | $966.74M | +11.1% |
| Q4 FY2024 | Dec 31, 2024 | $910.43M | +16.7% |
| Q3 FY2024 | Sep 30, 2024 | $991.12M | +16.3% |
| Q2 FY2024 | Jun 30, 2024 | $964.32M | +27.3% |
| Q1 FY2024 | Mar 31, 2024 | $869.83M | +5.5% |
| Q4 FY2023 | Dec 31, 2023 | $780.35M | +17.5% |
| Q3 FY2023 | Sep 30, 2023 | $852.32M | +56.1% |
| Q2 FY2023 | Jun 30, 2023 | $757.29M | +24.0% |
| Q1 FY2023 | Mar 31, 2023 | $824.77M | +17.6% |
| Q4 FY2022 | Dec 31, 2022 | $663.98M | -14.6% |
| Q3 FY2022 | Sep 30, 2022 | $545.92M | -34.1% |
| Q2 FY2022 | Jun 30, 2022 | $610.88M | -28.4% |
| Q1 FY2022 | Mar 31, 2022 | $701.25M | -6.6% |
| Q4 FY2021 | Dec 31, 2021 | $777.33M | +1.2% |
| Q3 FY2021 | Sep 30, 2021 | $828.83M | +5.9% |
| Q2 FY2021 | Jun 30, 2021 | $852.79M | +4.3% |
| Q1 FY2021 | Mar 31, 2021 | $750.57M | +160.3% |
| Q4 FY2020 | Dec 31, 2020 | $768.46M | +123.0% |
| Q3 FY2020 | Sep 30, 2020 | $782.29M | +97.7% |
| Q2 FY2020 | Jun 30, 2020 | $817.57M | +87.5% |
| Q1 FY2020 | Mar 31, 2020 | $288.30M | -37.5% |
| Q4 FY2019 | Dec 31, 2019 | $344.66M | -28.3% |
| Q3 FY2019 | Sep 30, 2019 | $395.75M | +46.1% |
| Q2 FY2019 | Jun 30, 2019 | $435.92M | +53.1% |
| Q1 FY2019 | Mar 31, 2019 | $461.50M | +50.2% |
| Q4 FY2018 | Dec 31, 2018 | $480.82M | +209.5% |
| Q3 FY2018 | Sep 30, 2018 | $270.83M | +55.7% |
| Q2 FY2018 | Jun 30, 2018 | $284.75M | +106.3% |
| Q1 FY2018 | Mar 31, 2018 | $307.25M | +97.7% |
| Q4 FY2017 | Dec 31, 2017 | $155.37M | -9.6% |
| Q3 FY2017 | Sep 30, 2017 | $173.97M | -4.6% |
| Q2 FY2017 | Jun 30, 2017 | $138.01M | – |
| Q1 FY2017 | Mar 31, 2017 | $155.39M | – |
| Q4 FY2016 | Dec 31, 2016 | $171.89M | – |
| Q3 FY2016 | Sep 30, 2016 | $182.33M | – |
See a number that looks wrong?